Immune system involvement in the pathogenesis of JC Virus induced PML What is learned from studies of patients with underlying diseases and therapies as risk factors

Frontiers in Immunology

Volumn 6, Issue MAR, 2015, Pages

  Monaco, Maria Chiara G ^a   Major, Eugene O ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

Immunomodulatory therapy; JCV; Multiple Sclerosis; Natalizumab; Progressive Multifocal Leukoencephalopathy; T cell immune response

Indexed keywords

NATALIZUMAB;

ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNITY; INTRACELLULAR SPACE; JC VIRUS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RISK ASSESSMENT; RISK FACTOR; SIGNAL TRANSDUCTION;

EID: 84926672575     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2015.00159     Document Type: Article

References (43)

1. Berger, J.R., Houff, S.A., Gurwell, J., Vega, N., Miller, C.S., and Danaher, R.J. (2013). JC virus antibody status underestimates infection rates. Ann Neurol 74, 84-90.
2. Bloomgren, G., Richman, S., Hotermans, C., Subramanyam, M., Goelz, S., Natarajan, A., Lee, S., Plavina, T., Scanlon, J.V., Sandrock, A., and Bozic, C. (2012). Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 366, 1870-1880.
3. Chalkias, S., Dang, X., Bord, E., Stein, M.C., Kinkel, R.P., Sloane, J.A., Donnelly, M., Ionete, C., Houtchens, M.K., Buckle, G.J., Batson, S., and Koralnik, I.J. (2014). JC virus reactivation during prolonged natalizumab monotherapy for multiple sclerosis. Ann Neurol 75, 925-934.
4. Chen, Y., Bord, E., Tompkins, T., Miller, J., Tan, C.S., Kinkel, R.P., Stein, M.C., Viscidi, R.P., Ngo, L.H., and Koralnik, I.J. (2009). Asymptomatic reactivation of JC virus in patients treated with natalizumab. N Engl J Med 361, 1067-1074.
5. Du Pasquier, R.A., Clark, K.W., Smith, P.S., Joseph, J.T., Mazullo, J.M., De Girolami, U., Letvin, N.L., and Koralnik, I.J. (2001). JCV-specific cellular immune response correlates with a favorable clinical outcome in HIV-infected individuals with progressive multifocal leukoencephalopathy. J Neurovirol 7, 318-322.
6. Du Pasquier, R.A., Kuroda, M.J., Schmitz, J.E., Zheng, Y., Martin, K., Peyerl, F.W., Lifton, M., Gorgone, D., Autissier, P., Letvin, N.L., and Koralnik, I.J. (2003). Low frequency of cytotoxic T lymphocytes against the novel HLA-A*0201-restricted JC virus epitope VP1(p36) in 326 patients with proven or possible progressive multifocal leukoencephalopathy. J Virol 77, 11918-11926.
7. Feagan, B.G., Rutgeerts, P., Sands, B.E., Hanauer, S., Colombel, J.F., Sandborn, W.J., Van Assche, G., Axler, J., Kim, H.J., Danese, S., Fox, I., Milch, C., Sankoh, S., Wyant, T., Xu, J., and Parikh, A. (2013). Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 369, 699-710.
8. Ferenczy, M.W., Marshall, L.J., Nelson, C.D., Atwood, W.J., Nath, A., Khalili, K., and Major, E.O. (2012). Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev 25, 471-506.
9. Fox, R.J., and Rudick, R.A. (2012). Risk stratification and patient counseling for natalizumab in multiple sclerosis. Neurology 78, 436-437.
10. Frohman, E.M., Monaco, M.C., Remington, G., Ryschkewitsch, C., Jensen, P.N., Johnson, K., Perkins, M., Liebner, J., Greenberg, B., Monson, N., Frohman, T.C., Douek, D., and Major, E.O. (2014). JC virus in CD34+ and CD19+ cells in patients with multiple sclerosis treated with natalizumab. JAMA Neurol 71, 596-602.
11. Gheuens, S., Bord, E., Kesari, S., Simpson, D.M., Gandhi, R.T., Clifford, D.B., Berger, J.R., Ngo, L., and Koralnik, I.J. (2011). Role of CD4+ and CD8+ T-cell responses against JC virus in the outcome of patients with progressive multifocal leukoencephalopathy (PML) and PML with immune reconstitution inflammatory syndrome. J Virol 85, 7256-7263.
12. Goldmann, C., Petry, H., Frye, S., Ast, O., Ebitsch, S., Jentsch, K.D., Kaup, F.J., Weber, F., Trebst, C., Nisslein, T., Hunsmann, G., Weber, T., and Luke, W. (1999). Molecular cloning and expression of major structural protein VP1 of the human polyomavirus JC virus: formation of virus-like particles useful for immunological and therapeutic studies. J Virol 73, 4465-4469.
13. Gorelik, L., Lerner, M., Bixler, S., Crossman, M., Schlain, B., Simon, K., Pace, A., Cheung, A., Chen, L.L., Berman, M., Zein, F., Wilson, E., Yednock, T., Sandrock, A., Goelz, S.E., and Subramanyam, M. (2010). Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol 68, 295-303.
14. Gupta, S., and Weinstock-Guttman, B. (2014). Natalizumab for multiple sclerosis: appraising risk versus benefit, a seemingly demanding tango. Expert Opin Biol Ther 14, 115-126.
15. Hamilton, R.S., Gravell, M., and Major, E.O. (2000). Comparison of antibody titers determined by hemagglutination inhibition and enzyme immunoassay for JC virus and BK virus. J Clin Microbiol 38, 105-109.
16. Hampras, S.S., Viscidi, R.P., Helzlsouer, K.J., Lee, J.H., Fulp, W.J., Giuliano, A.R., Platz, E.A., and Rollison, D.E. (2014). Prospective study of seroreactivity to JC virus T-antigen and risk of colorectal cancers and adenomas. Cancer Epidemiol Biomarkers Prev 23, 2591-2596.
17. Hendel-Chavez, H., De Goer De Herve, M.G., Giannesini, C., Mazet, A.A., Papeix, C., Louapre, C., Chardain, A., Boutarfa, N., Theaudin, M., Adams, D., Gasnault, J., Stankoff, B., and Taoufik, Y. (2013). Immunological hallmarks of JC virus replication in multiple sclerosis patients on long364 term natalizumab therapy. J Virol 87, 6055-6059.
18. Houff, S.A., Major, E.O., Katz, D.A., Kufta, C.V., Sever, J.L., Pittaluga, S., Roberts, J.R., Gitt, J., Saini, N., and Lux, W. (1988). Involvement of JC virus-infected mononuclear cells from the bone marrow and spleen in the pathogenesis of progressive multifocal leukoencephalopathy. N Engl J Med 318, 301-305.
19. Jelcic, I., Aly, L., Binder, T.M., Jelcic, I., Bofill-Mas, S., Planas, R., Demina, V., Eiermann, T.H., Weber, T., Girones, R., Sospedra, M., and Martin, R. (2013). T cell epitope mapping of JC polyoma virus371 encoded proteome reveals reduced T cell responses in HLA-DRB1*04:01+ donors. J Virol 87, 3393-3408.
20. Jilek, S., Jaquiery, E., Hirsch, H.H., Lysandropoulos, A., Canales, M., Guignard, L., Schluep, M., Pantaleo, G., and Du Pasquier, R.A. (2010). Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study. Lancet Neurol 9, 264-272.
21. Koralnik, I.J., Du Pasquier, R.A., Kuroda, M.J., Schmitz, J.E., Dang, X., Zheng, Y., Lifton, M., and Letvin, N.L. (2002). Association of prolonged survival in HLA-A2+ progressive multifocal leukoencephalopathy patients with a CTL response specific for a commonly recognized JC virus epitope. J Immunol 168, 499-504.
22. Major, E.O. (2009). Reemergence of PML in natalizumab-treated patients-new cases, same concerns. N Engl J Med 361, 1041-1043.
23. Major, E.O. (2010). Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med 61, 35-47.
24. Major, E.O., Frohman, E., and Douek, D. (2013). JC viremia in natalizumab-treated patients with multiple sclerosis. N Engl J Med 368, 2240-2241.
25. Marshall, L.J., Dunham, L., and Major, E.O. (2010). Transcription factor Spi-B binds unique sequences present in the tandem repeat promoter/enhancer of JC virus and supports viral activity. J Gen Virol 91, 3042-3052.
26. Marshall, L.J., Ferenczy, M.W., Daley, E.L., Jensen, P.N., Ryschkewitsch, C.F., and Major, E.O. (2014). Lymphocyte gene expression and JC virus noncoding control region sequences are linked with the risk of progressive multifocal leukoencephalopathy. J Virol 88, 5177-5183.
27. Marshall, L.J., and Major, E.O. Molecular regulation of JC virus tropism: insights into potential therapeutic targets for progressive multifocal leukoencephalopathy. J Neuroimmune Pharmacol 5, 404-417.
28. Marshall, L.J., Moore, L.D., Mirsky, M.M., and Major, E.O. (2012). JC virus promoter/enhancers contain TATA box-associated Spi-B-binding sites that support early viral gene expression in primary astrocytes. J Gen Virol 93, 651-661.
29. Marzocchetti, A., Tompkins, T., Clifford, D.B., Gandhi, R.T., Kesari, S., Berger, J.R., Simpson, D.M., Prosperi, M., De Luca, A., and Koralnik, I.J. (2009). Determinants of survival in progressive multifocal leukoencephalopathy. Neurology 73, 1551-1558.
30. Meira, M., Sievers, C., Hoffmann, F., Derfuss, T., Kuhle, J., Kappos, L., and Lindberg, R.L. (2014). MiR-126: a novel route for natalizumab action? Mult Scler 20, 1363-1370.
31. Niv, Y., Vilkin, A., and Levi, Z. (2010). Patients with sporadic colorectal cancer or advanced adenomatous polyp have elevated anti-JC virus antibody titer in comparison with healthy controls: a cross406 sectional study. J Clin Gastroenterol 44, 489-494.
32. Padgett, B.L., and Walker, D.L. (1973). Prevalence of antibodies in human sera against JC virus, an isolate from a case of progressive multifocal leukoencephalopathy. J Infect Dis 127, 467-470.
33. Perkins, M.R., Ryschkewitsch, C., Liebner, J.C., Monaco, M.C., Himelfarb, D., Ireland, S., Roque, A., Edward, H.L., Jensen, P.N., Remington, G., Abraham, T., Abraham, J., Greenberg, B., Kaufman, C., Laganke, C., Monson, N.L., Xu, X., Frohman, E., Major, E.O., and Douek, D.C. (2012). Changes in JC virus-specific T cell responses during natalizumab treatment and in natalizumab-associated progressive multifocal leukoencephalopathy. PLoS Pathog 8, e1003014.
34. Planas, R., Jelcic, I., Schippling, S., Martin, R., and Sospedra, M. (2012). Natalizumab treatment perturbs memory-and marginal zone-like B-cell homing in secondary lymphoid organs in multiple sclerosis. Eur J Immunol 42, 790-798.
35. Plavina, T., Subramanyam, M., Bloomgren, G., Richman, S., Pace, A., Lee, S., Schlain, B., Campagnolo, D., Belachew, S., and Ticho, B. (2014). Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol. Rollison, D.E. (2010). JC virus infection: a cause of colorectal cancer? J Clin Gastroenterol 44, 466-468.
36. Sandborn, W.J., Feagan, B.G., Rutgeerts, P., Hanauer, S., Colombel, J.F., Sands, B.E., Lukas, M., Fedorak, R.N., Lee, S., Bressler, B., Fox, I., Rosario, M., Sankoh, S., Xu, J., Stephens, K., Milch, C., and Parikh, A. (2013). Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 369, 711-721.
37. Tan, C.S., Broge, T.A., Jr., Ngo, L., Gheuens, S., Viscidi, R., Bord, E., Rosenblatt, J., Wong, M., Avigan, D., and Koralnik, I.J. (2014). Immune reconstitution after allogeneic hematopoietic stem cell transplantation is associated with selective control of JC virus reactivation. Biol Blood Marrow Transplant 20, 992-999.
38. Tan, C.S., Dezube, B.J., Bhargava, P., Autissier, P., Wuthrich, C., Miller, J., and Koralnik, I.J. (2009). Detection of JC virus DNA and proteins in the bone marrow of HIV-positive and HIV-negative patients: implications for viral latency and neurotropic transformation. J Infect Dis 199, 881-888.
39. Tyler, K.L. (2010). Progressive multifocal leukoencephalopathy: can we reduce risk in patients receiving biological immunomodulatory therapies? Ann Neurol 68, 271-274.
40. Viscidi, R.P., Rollison, D.E., Viscidi, E., Clayman, B., Rubalcaba, E., Daniel, R., Major, E.O., and Shah, K.V. (2003). Serological cross-reactivities between antibodies to simian virus 40, BK virus, and JC virus assessed by virus-like-particle-based enzyme immunoassays. Clin Diagn Lab Immunol 10, 278-285.
41. Weber, F., Goldmann, C., Kramer, M., Kaup, F.J., Pickhardt, M., Young, P., Petry, H., Weber, T., and Luke, W. (2001). Cellular and humoral immune response in progressive multifocal leukoencephalopathy. Ann Neurol 49, 636-642.
42. Yang, W., Beaudoin, E.L., Lu, L., Du Pasquier, R.A., Kuroda, M.J., Willemsen, R.A., Koralnik, I.J., and Junghans, R.P. (2007). Chimeric immune receptors (CIRs) specific to JC virus for immunotherapy in progressive multifocal leukoencephalopathy (PML). Int Immunol 19, 1083-1093.
43. Zohren, F., Toutzaris, D., Klarner, V., Hartung, H.P., Kieseier, B., and Haas, R. (2008). The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans. Blood 111, 3893-3895.